These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 15497025

  • 1. Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in rats.
    Ravindranath TM, Goto M, Demir M, Tobu M, Kujawski MF, Hoppensteadt D, Samonte V, Iqbal O, Sayeed MM, Fareed J.
    Clin Appl Thromb Hemost; 2004 Oct; 10(4):379-85. PubMed ID: 15497025
    [Abstract] [Full Text] [Related]

  • 2. Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis.
    Ravindranath TM, Goto M, Iqbal O, Florian-Kujawski M, Hoppensteadt D, Hammadeh R, Sayeed MM, Fareed J.
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):362-8. PubMed ID: 17911187
    [Abstract] [Full Text] [Related]

  • 3. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B, Kılıç N, Şimşek E, Dallar Y.
    J Clin Res Pediatr Endocrinol; 2012 Sep; 4(3):146-50. PubMed ID: 22985614
    [Abstract] [Full Text] [Related]

  • 4. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz HO.
    Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
    [Abstract] [Full Text] [Related]

  • 5. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu İ, Ersoz HO.
    Endocrine; 2009 Dec; 36(3):473-8. PubMed ID: 19859836
    [Abstract] [Full Text] [Related]

  • 6. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 7. Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.
    Yüzbaşıoğlu B, Ustaoğlu M, Yüzbaşıoğlu Ş, Akbulut UE, Özdil K.
    Turk J Gastroenterol; 2019 Dec; 30(12):1025-1029. PubMed ID: 31854307
    [Abstract] [Full Text] [Related]

  • 8. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor.
    Tobu M, Iqbal O, Fareed D, Chatha M, Hoppensteadt D, Bansal V, Fareed J.
    Clin Appl Thromb Hemost; 2004 Jul; 10(3):225-32. PubMed ID: 15247979
    [Abstract] [Full Text] [Related]

  • 9. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study.
    Bladbjerg EM, Madsen JS, Kristensen SR, Abrahamsen B, Brixen K, Mosekilde L, Jespersen J.
    J Thromb Haemost; 2003 Jun; 1(6):1208-14. PubMed ID: 12871321
    [Abstract] [Full Text] [Related]

  • 10. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 11. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice.
    Renckens R, Roelofs JJ, ter Horst SA, van 't Veer C, Havik SR, Florquin S, Wagenaar GT, Meijers JC, van der Poll T.
    J Immunol; 2005 Nov 15; 175(10):6764-71. PubMed ID: 16272333
    [Abstract] [Full Text] [Related]

  • 12. [Influences of ulinastatin on acute lung injury and time phase changes of coagulation parameters in rats with burn-blast combined injuries].
    Liu W, Chai JK.
    Zhonghua Shao Shang Za Zhi; 2018 Jan 20; 34(1):32-39. PubMed ID: 29374925
    [Abstract] [Full Text] [Related]

  • 13. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 14. Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
    Koldas M, Gummus M, Seker M, Seval H, Hulya K, Dane F, Kural A, Gumus A, Salepci T, Turhal NS.
    Clin Lung Cancer; 2008 Mar 01; 9(2):112-5. PubMed ID: 18501098
    [Abstract] [Full Text] [Related]

  • 15. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 16. Thrombin-activatable fibrinolysis inhibitor is activated in an instant blood-mediated inflammatory reaction after intraportal islet transplant.
    Wang S, Zhao Z, Cong Z, Suo G.
    Exp Clin Transplant; 2014 Feb 01; 12(1):62-6. PubMed ID: 24188431
    [Abstract] [Full Text] [Related]

  • 17. Utilizing Plasma Composition Data to Help Determine Procoagulant Dynamics in Patients with Thermal Injury: A Computational Assessment.
    Bravo MC, Tejiram S, McLawhorn MM, Moffatt LT, Orfeo T, Jett-Tilton M, Pusateri AE, Shupp JW, Brummel-Ziedins KE.
    Mil Med; 2019 Mar 01; 184(Suppl 1):392-399. PubMed ID: 30901410
    [Abstract] [Full Text] [Related]

  • 18. Contribution of gene expression to metabolic fluxes in hypermetabolic livers induced through burn injury and cecal ligation and puncture in rats.
    Banta S, Vemula M, Yokoyama T, Jayaraman A, Berthiaume F, Yarmush ML.
    Biotechnol Bioeng; 2007 May 01; 97(1):118-37. PubMed ID: 17009336
    [Abstract] [Full Text] [Related]

  • 19. A novel model of burn-blast combined injury and its phasic changes of blood coagulation in rats.
    Chai JK, Liu W, Deng HP, Cai JH, Hu QG, Zou XF, Shen CA, Yin HN, Han YF, Zhang XB, Chi YF, Ma L, Sun TJ, Feng R, Lan YT.
    Shock; 2013 Oct 01; 40(4):297-302. PubMed ID: 23364430
    [Abstract] [Full Text] [Related]

  • 20. Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs.
    Jessen LR, Wiinberg B, Kjelgaard-Hansen M, Jensen AL, Rozanski E, Kristensen AT.
    Vet Clin Pathol; 2010 Sep 01; 39(3):296-301. PubMed ID: 20487433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.